Trusted Resources: Education
Scientific literature and patient education texts
Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, but Many Unknowns Remain
source: PharmacoEconomics
year: 2021
authors: Skedgel C
summary/abstract:This supplement includes five papers that add to our understanding of the costs, health-related quality of life, and cost effectiveness of different treatments for spinal muscular atrophy (SMA), as well as patient preferences for treatment. SMA is a severe, inherited neuromuscular disease with an incidence of approximately 1 in 10,000 live births. SMA has received increased attention with the recent US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of the gene therapy Zolgensma®, described as ‘the world’s most expensive drug’, for paediatric patients with the severe SMA type 1 or up to three copies of the gene SMN2. SMA type 0 is typically associated with foetal or neonatal death, while SMA type 4 is the mildest form and typically emerges in adulthood. Patients with SMA type 1 are unable to sit unassisted and their life expectancy is not typically more than 2–3 years.
organization: Office of Health Economics, London, UK. cskedgel@ohe.org.DOI: 10.1007/s40273-021-01119-1
read more
Related Content
-
Living With Adult Spinal Muscular AtrophyMark Aldrich is a sharp, thoughtful 52-y...
-
The Fighting for Kaiden FoundationThe Fighting for Kaiden Foundation is a ...
-
Looking After Your Child Who Has Had a Recent Diagnosis of SMA Type 3Your child should receive care from memb...
-
Caregiving for a Young Adult With SMAOpen lines of communication are importan...
-
Caregivers Need Information About Help With Future Care, Study FindsCaregivers of children with spinal muscu...
-
SMA My WayIt’s not always easy to find life hack...
-
Living Well With SMASpinal muscular atrophy (SMA) is a rare ...